What is AlphaVax?
AlphaVax Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering vaccine development. Leveraging proprietary RNA particle technology, the company is focused on creating innovative vaccines for both human and veterinary use, with a strategic emphasis on anti-infective and anti-cancer applications, particularly in the realm of cancer immunotherapy. The company has cultivated a robust pipeline of seven vaccine candidates targeting critical areas such as human cytomegalovirus, influenza A virus, prostate cancer, and HIV-1. Having successfully navigated multiple Phase 1 clinical trials, AlphaVax's novel approach aims to harness the immune system to identify and neutralize various cancers, showing encouraging outcomes in improving patient survival rates.
How much funding has AlphaVax raised?
AlphaVax has raised a total of $31.9M across 3 funding rounds:
Series B
$8.2M
Series C
$11M
Series E
$12.7M
Series B (2000): $8.2M, investors not publicly disclosed
Series C (2000): $11M, investors not publicly disclosed
Series E (2007): $12.7M, investors not publicly disclosed
What's next for AlphaVax?
The substantial enterprise-level funding indicates AlphaVax is poised for significant expansion and the advancement of its vaccine candidates through later-stage clinical trials. This capital injection is expected to accelerate the development of their anti-cancer and anti-infective vaccines, potentially bringing them closer to market approval and widespread application. The company's focus on immunotherapy and its diverse portfolio suggest a strategic direction aimed at addressing unmet medical needs in both oncology and infectious diseases, positioning AlphaVax for substantial growth and impact in the biopharmaceutical sector.
See full AlphaVax company page
